Studies of total spending including prescription costs answer a broader question than a comparison of medical bills. SHINE-ASCVD examined one year of medical costs in adults with existing cardiovascular disease [1].
Who was compared
The U.S. claims study matched 770 adults using semaglutide 2.4 mg to 3,080 controls. All had overweight or obesity and atherosclerotic cardiovascular disease. The treated group had prescription coverage on at least 80% of follow-up days [1].
Mean annual medical costs were $16,201 with semaglutide and $20,840 in controls. The modeled ratio was 0.78 (95% CI 0.67 to 0.89). Inpatient costs accounted for much of the observed difference [1].
What the cost difference means
Selecting patients by later adherence can favor those able to stay on treatment. Matching at baseline cannot account for all differences. The study did not establish net savings after adding the price of treatment.
Evidence on cardiovascular outcomes in randomized trials comes from a different study design. A change in event risk still leaves a separate question about drug spending and who pays it.
Novo Nordisk funded SHINE-ASCVD. These are medical cost estimates for a selected insured population.